Related Experiment Video

Updated: May 28, 2026

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

A case-control histological study on the effects of phlebotomy in patients with chronic hepatitis C

Massimo Sartori1, Silvano Andorno, Angelo Rossini

  • 1Gastroenterology Unit, AOU Maggiore della Carita', Novara, Italy. sartori@fauser.edu

European Journal of Gastroenterology & Hepatology
|October 18, 2011
PubMed

Insights

Long-term phlebotomy significantly improved liver histology in patients with chronic hepatitis C (CHC) who did not respond to interferon therapy. Iron depletion via phlebotomy is effective in managing CHC progression when other treatments fail.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Chronic hepatitis C (CHC) is a significant cause of liver disease.
  • Interferon-based therapies have limited efficacy in some patients.
  • Iron overload can exacerbate liver fibrosis in CHC.

Purpose of the Study:

  • To evaluate the effectiveness of long-term phlebotomy in achieving histological improvement (HI) in CHC patients.
  • To compare phlebotomy with interferon-based therapy in nonresponders (IBT-NR).

Main Methods:

  • Retrospective analysis of liver biopsies from 69 Caucasian HCV-RNA-positive CHC patients.
  • HI defined by reduction in staging or grading scores (Knodel's Activity Index).
  • Comparison between 30 phlebotomized patients and 39 IBT-NR patients over 56 ± 28 months.

Main Results:

  • Histological improvement (HI) observed in 50% of phlebotomy patients vs. 15% of IBT-NR patients (P=0.002).
  • Significant reductions in AST, ALT, and GGT serum levels in phlebotomized patients.
  • Phlebotomy and lower initial histological grading score independently predicted HI.

Conclusions:

  • Long-term phlebotomy effectively induces histological improvement in CHC patients.
  • Iron depletion via phlebotomy is a viable strategy for CHC management when other therapies fail.
  • Phlebotomy demonstrates efficacy in attenuating CHC progression.
Abstract

More Related Videos

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...